150 related articles for article (PubMed ID: 17080753)
1. Comparison of models for average bioequivalence in replicated crossover designs.
Willavize SA; Morgenthien EA
Pharm Stat; 2006; 5(3):201-11. PubMed ID: 17080753
[TBL] [Abstract][Full Text] [Related]
2. On statistical power for average bioequivalence testing under replicated crossover designs.
Wan H; Chow SC
J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
[TBL] [Abstract][Full Text] [Related]
3. [Applying multilevel models in evaluation of bioequivalence (I)].
Liu QL; Shen ZZ; Chen F; Li XS; Yang M
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1302-6. PubMed ID: 20193320
[TBL] [Abstract][Full Text] [Related]
4. A three-step procedure for assessing bioequivalence in the general mixed model framework.
Vuorinen J; Turunen J
Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
[TBL] [Abstract][Full Text] [Related]
5. Testing for bioequivalence of highly variable drugs from TR-RT crossover designs with heterogeneous residual variances.
Kang Q; Vahl CI
Pharm Stat; 2017 Sep; 16(5):361-377. PubMed ID: 28620937
[TBL] [Abstract][Full Text] [Related]
6. Use of the repeated cross-over designs in assessing bioequivalence.
Liu JP
Stat Med; 1995 May 15-30; 14(9-10):1067-78; discussion 1079-80. PubMed ID: 7569501
[TBL] [Abstract][Full Text] [Related]
7. Equivalence assessment for interchangeability based on two-sided tests.
Dong X; Tsong Y
J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
[TBL] [Abstract][Full Text] [Related]
8. The effect of variability and carryover on average bioequivalence assessment: a simulation study.
Sánchez MP; Ocaña J; Carrasco JL
Pharm Stat; 2011; 10(2):135-42. PubMed ID: 22432131
[TBL] [Abstract][Full Text] [Related]
9. Subject-by-formulation interaction in determinations of individual bioequivalence: bias and prevalence.
Endrenyi L; Tothfalusi L
Pharm Res; 1999 Feb; 16(2):186-90. PubMed ID: 10100301
[TBL] [Abstract][Full Text] [Related]
10. Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.
Diaz FJ; Berg MJ; Krebill R; Welty T; Gidal BE; Alloway R; Privitera M
Clin Pharmacokinet; 2013 Dec; 52(12):1033-43. PubMed ID: 24085600
[TBL] [Abstract][Full Text] [Related]
11. Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products.
Patterson SD; Zariffa NM; Montague TH; Howland K
Eur J Clin Pharmacol; 2001 Nov; 57(9):663-70. PubMed ID: 11791897
[TBL] [Abstract][Full Text] [Related]
12. The subject-by-formulation interaction in multivariate bioequivalence.
Cao L; Mathew T
J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
[TBL] [Abstract][Full Text] [Related]
13. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
14. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
Molins E; Cobo E; Ocaña J
Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
[TBL] [Abstract][Full Text] [Related]
15. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
Nguyen TT; Bazzoli C; Mentré F
Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
[TBL] [Abstract][Full Text] [Related]
16. Tolerance intervals for assessing individual bioequivalence.
Brown EB; Iyer HK; Wang CM
Stat Med; 1997 Apr; 16(7):803-20. PubMed ID: 9131767
[TBL] [Abstract][Full Text] [Related]
17. The analysis of bioequivalence with respect to TMAX under a 2 x 2 crossover design.
Have TR; Ten Chinchilli VM
J Biopharm Stat; 1995 Jul; 5(2):185-99. PubMed ID: 7581427
[TBL] [Abstract][Full Text] [Related]
18. On assessment of bioequivalence under a higher-order crossover design.
Chow SC; Liu JP
J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
[TBL] [Abstract][Full Text] [Related]
19. Analysis of multiple-dose bioequivalence studies.
Chinchilli VM; Esinhart JD; Barr WH
J Biopharm Stat; 1994 Nov; 4(3):423-35. PubMed ID: 7881454
[TBL] [Abstract][Full Text] [Related]
20. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
